{"nctId":"NCT04657003","briefTitle":"A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight","startDateStruct":{"date":"2021-03-29","type":"ACTUAL"},"conditions":["Type 2 Diabetes","Overweight","Obesity"],"count":938,"armGroups":[{"label":"10 milligrams (mg) Tirzepatide","type":"EXPERIMENTAL","interventionNames":["Drug: Tirzepatide"]},{"label":"15 mg Tirzepatide","type":"EXPERIMENTAL","interventionNames":["Drug: Tirzepatide"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo"]}],"interventions":[{"name":"Tirzepatide","otherNames":["LY3298176"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Have Type 2 Diabetes (T2DM) with HbA1c ≥7% to ≤10% at screening, on stable therapy for the last 3 months prior to screening. T2DM may be treated with diet/exercise alone or any oral glycemic-lowering agent (as per local labeling) EXCEPT dipeptidyl peptidase 4 (DPP-4) inhibitors or glucagon like peptide-1 receptor agonists (GLP-1 RAs)\n* Have a BMI of ≥27 kg/m²\n* Are overweight or have obesity\n* Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight\n* Are at least 18 years of age and age of majority per local laws and regulations\n\nExclusion Criteria:\n\n* Have Type 1 diabetes mellitus, history of ketoacidosis or hyperosmolar state/coma or any other types of diabetes except T2DM\n* Have at least 2 confirmed fasting self-monitoring blood glucose (SMBG) values \\>270 mg/dL(on 2 nonconsecutive days) prior to Visit 3\n* Have proliferative diabetic retinopathy OR diabetic macular edema OR non-proliferative diabetic retinopathy that requires acute treatment\n* Have self-reported change in body weight \\>5kg within 3 months prior to screening\n* Have had a history of chronic or acute pancreatitis\n* Change in body weight greater than 5 kg within 3 months prior to starting study\n* Obesity induced by other endocrinologic disorders or monogenetic or syndromic forms of obesity\n* Family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)\n* History of significant active or unstable major depressive disorder (MDD) or other severe psychiatric disorder within the last 2 years\n* Any lifetime history of a suicide attempt","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change From Baseline in Body Weight","description":"Least Squares Mean (LSMean) calculated using Mixed Model Repeated Measures (MMRM) model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Type of Antihyperglycemic Medication (AHM) Used at Randomization + Treatment + Time + Treatment\\*Time (Type III sum of squares).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.3","spread":"0.49"},{"groupId":"OG001","value":"-13.4","spread":"0.48"},{"groupId":"OG002","value":"-15.7","spread":"0.49"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Who Achieve ≥5% Body Weight Reduction From Baseline","description":"Percentage of participants who achieve ≥5% body weight reduction from baseline","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.55","spread":null},{"groupId":"OG001","value":"81.55","spread":null},{"groupId":"OG002","value":"86.41","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieve ≥10% Body Weight Reduction From Baseline","description":"Percentage of participants who achieve ≥10% body weight reduction from baseline","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.68","spread":null},{"groupId":"OG001","value":"63.43","spread":null},{"groupId":"OG002","value":"69.58","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieve ≥15% Body Weight Reduction From Baseline","description":"Percentage of participants who achieve ≥15% body weight reduction from baseline","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.57","spread":null},{"groupId":"OG001","value":"41.42","spread":null},{"groupId":"OG002","value":"51.78","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieve ≥20% Body Weight Reduction From Baseline","description":"Percentage of participants who achieve ≥20% body weight reduction from baseline","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.96","spread":null},{"groupId":"OG001","value":"22.98","spread":null},{"groupId":"OG002","value":"33.98","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Absolute Body Weight","description":"LSMean calculated using MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Type of AHM Used at Randomization + Treatment + Time + Treatment\\*Time (Type III sum of squares).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.2","spread":"0.51"},{"groupId":"OG001","value":"-13.5","spread":"0.51"},{"groupId":"OG002","value":"-15.6","spread":"0.51"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Body Mass Index (BMI)","description":"LSMean calculated using MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Type of AHM Used at Randomization + Treatment + Time + Treatment\\*Time (Type III sum of squares).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.2","spread":"0.19"},{"groupId":"OG001","value":"-4.9","spread":"0.18"},{"groupId":"OG002","value":"-5.7","spread":"0.19"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Hemoglobin A1c (HbA1c)","description":"LSMean calculated using MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Type of AHM Used at Randomization + Treatment + Time + Treatment\\*Time (Type III sum of squares).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.16","spread":"0.067"},{"groupId":"OG001","value":"-2.14","spread":"0.060"},{"groupId":"OG002","value":"-2.22","spread":"0.060"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieve HbA1c <7%","description":"Percentage of participants who achieve HbA1c \\<7%","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.31","spread":null},{"groupId":"OG001","value":"90.03","spread":null},{"groupId":"OG002","value":"90.67","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieve HbA1c ≤6.5%","description":"Percentage of participants who achieve HbA1c ≤6.5%","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.52","spread":null},{"groupId":"OG001","value":"84.05","spread":null},{"groupId":"OG002","value":"86.67","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieve HbA1c <5.7%","description":"Percentage of participants who achieve HbA1c \\<5.7%","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.76","spread":null},{"groupId":"OG001","value":"50.17","spread":null},{"groupId":"OG002","value":"55.33","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Glucose","description":"LSMean calculated using MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Type of AHM Used at Randomization + Baseline HbA1c Group (\\<=8.5%, \\>8.5%) + Treatment + Time + Treatment\\*Time (Type III sum of squares).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.42","spread":"2.281"},{"groupId":"OG001","value":"-49.20","spread":"1.940"},{"groupId":"OG002","value":"-51.67","spread":"1.970"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Waist Circumference","description":"LSMean calculated using MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Type of AHM Used at Randomization + Treatment + Time + Treatment\\*Time (Type III sum of squares).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.4","spread":"0.51"},{"groupId":"OG001","value":"-11.2","spread":"0.50"},{"groupId":"OG002","value":"-13.8","spread":"0.51"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Total Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg)","description":"Results are reported as model-based estimates and standard error (SE) from MMRM analysis using log transformation.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.13","spread":"1.135"},{"groupId":"OG001","value":"-2.58","spread":"0.755"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Low Density Lipoprotein (LDL) Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg)","description":"Results are reported as model-based estimates and SE from MMRM analysis using log transformation.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.29","spread":"1.874"},{"groupId":"OG001","value":"2.72","spread":"1.264"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in High Density Lipoprotein (HDL) Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg)","description":"Results are reported as model-based estimates and SE from MMRM analysis using log transformation.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.10","spread":"1.048"},{"groupId":"OG001","value":"8.19","spread":"0.782"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Very Low Density Lipoprotein (VLDL) Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg)","description":"Results are reported as model-based estimates and SE from MMRM analysis using log transformation.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.0","spread":"2.18"},{"groupId":"OG001","value":"-27.9","spread":"1.16"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Triglycerides (Pooled Doses of Tirzepatide 10 mg and 15 mg)","description":"Results are reported as model-based estimates and SE from MMRM analysis using log transformation.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.8","spread":"2.32"},{"groupId":"OG001","value":"-28.6","spread":"1.22"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Non-High Density Lipoprotein (Non-HDL) Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg)","description":"Results are reported as model-based estimates and SE from MMRM analysis using log transformation.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.30","spread":"1.573"},{"groupId":"OG001","value":"-6.64","spread":"1.001"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Free Fatty Acids (Pooled Doses of 10 mg and 15 mg Tirzepatide)","description":"Results are reported as model-based estimates and SE from MMRM analysis using log transformation.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"2.838"},{"groupId":"OG001","value":"-23.58","spread":"1.502"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Systolic Blood Pressure (SBP) (Pooled Doses of 10 mg and 15 mg Tirzepatide)","description":"LSMean was calculated using MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Type of AHM Used at Randomization + Treatment + Time + Treatment\\*Time (Type III sum of squares).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","spread":"0.74"},{"groupId":"OG001","value":"-7.2","spread":"0.52"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Diastolic Blood Pressure (DBP) (Pooled Doses of 10 mg and 15 mg Tirzepatide)","description":"LSMean was calculated using MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Type of AHM Used at Randomization + Treatment + Time + Treatment\\*Time (Type III sum of squares).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"0.45"},{"groupId":"OG001","value":"-2.6","spread":"0.31"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Fasting Insulin","description":"Results are reported as model-based estimates and SE from MMRM analysis using log transformation.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.5","spread":"3.39"},{"groupId":"OG001","value":"-29.6","spread":"2.28"},{"groupId":"OG002","value":"-40.3","spread":"1.99"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Short Form 36 Health Survey Version 2 (SF-36v2) Acute Form Physical Functioning Domain Score","description":"The SF-36v2 acute, 1-week recall version is a 36-item, generic, patient-administered measure designed to assess the following 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. The Physical-Functioning domain assesses limitations due to health \"now\" while the remaining domains assess functioning \"in the past week.\" Each domain is scored individually and information from these 8 domains are further aggregated into 2 health-component summary scores: Physical-Component Summary and Mental-Component Summary. Items are answered on Likert scales of varying lengths (3-, 5-, or 6- point scales).The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"0.40"},{"groupId":"OG001","value":"3.4","spread":"0.39"},{"groupId":"OG002","value":"3.8","spread":"0.40"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Impact of Weight on Quality of Life-Lite-Clinical Trials Version (IWQOL Lite-CT) Physical Function Composite Score","description":"The IWQOL-Lite-CT is a 20-item, obesity-specific patient reported outcome (PRO) instrument developed for use in obesity clinical trials. It assesses 2 primary domains of obesity-related health-related quality of life (HRQoL): physical (7 items), and psychosocial (13 items). A 5-item subset of the physical domain, the physical-function composite is also supported. Items in the physical-function composite describe physical impacts related to general and specific physical activities. All items in the physical domain are rated on either a 5-point frequency (\"never\" to \"always\") scale or a 5-point truth (\"not at all true\" to \"completely true\") scale. Total score of IWQOL-Lite-CT composite ranges from 0 to 100, with higher scores reflecting better quality of life.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.4","spread":"1.03"},{"groupId":"OG001","value":"14.3","spread":"1.00"},{"groupId":"OG002","value":"15.2","spread":"1.03"}]}]}]},{"type":"SECONDARY","title":"Population Pharmacokinetics (PopPK): Steady State Area Under the Concentration Curve (AUC) of Tirzepatide","description":"Each participant was assigned via the Interactive Web Response System (IWRS) to one of the sampling PK time windows of 1 to 24 hours, 24 to 96 hours, or 120 to 168 hours postdose. The steady state AUC was evaluated using Population PK modeling.","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"153000","spread":"19.5"},{"groupId":"OG001","value":"234000","spread":"19.2"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":23,"n":315},"commonTop":["Diarrhoea","Nausea","Covid-19","Vomiting","Decreased appetite"]}}}